• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

多中心非强化病变在胶质母细胞瘤中的回顾性研究。

Multicentric non-enhancing lesions in glioblastoma: A retrospective study.

机构信息

Neuro-oncology Unit, Davidoff Center, Rabin Medical Center, Petah Tikva, Israel.

Department of Radiology, Rabin Medical Center, Petah Tikva, Israel.

出版信息

J Clin Neurosci. 2021 Mar;85:20-26. doi: 10.1016/j.jocn.2020.11.050. Epub 2021 Jan 3.

DOI:10.1016/j.jocn.2020.11.050
PMID:33581785
Abstract

Glioblastoma (GBM) typically presents as a single lesion. Multicentric GBM are defined as well separated lesions on MRI (enhancing and non-enhancing). Multicentric GBM with non-enhancing lesions (MNE-GBM) are rarely described in literature. We aimed at describing the radiologic characteristics, treatment, and clinical course of those patients. The institutional neuropathological database was searched for GBM patients diagnosed between 1/1/2015 and 31/05/2018. All pre-operative MRI brain scans were reviewed to identify patients with MNE-GBM. Electronic medical records and follow-up MRI scans were reviewed to assess progression-free survival (PFS) and overall survival (OS). Out of 149 adult patients with newly diagnosed GBM, 12 met the inclusion criteria of MNE-GBM, all of them presented at least one enhancing lesion. Median follow-up for the MNE-GBM patients was 16.1 months. At last follow-up, all patients had recurrence (median PFS 7.6 months) and eleven patients had deceased. Median OS was 16.2 months (95% CI, 4.1-27.5). Eleven patients received radiotherapy concomitant with temozolomide as initial treatment. Radiation field included all the disease foci (enhancing and non-enhancing lesions) in 8 patients, five of them progressed within the non-enhancing lesion. Three patients did not receive radiation for the entire non-enhancing lesions, and two of them progressed within the non-irradiated areas. In conclusion, MNE-GBM is not rare, and has high risk of aggressive progression within the separate non-enhancing lesion.

摘要

胶质母细胞瘤(GBM)通常表现为单个病变。多灶性 GBM 定义为 MRI 上明显分隔的病变(增强和非增强)。文献中很少描述多灶性 GBM 伴非增强病变(MNE-GBM)。我们旨在描述这些患者的放射学特征、治疗和临床过程。在 2015 年 1 月 1 日至 2018 年 5 月 31 日期间,我们从机构神经病理学数据库中搜索诊断为 GBM 的患者。所有术前脑部 MRI 扫描均用于识别 MNE-GBM 患者。回顾电子病历和随访 MRI 扫描以评估无进展生存期(PFS)和总生存期(OS)。在 149 名新诊断为 GBM 的成年患者中,有 12 名符合 MNE-GBM 的纳入标准,所有患者均至少存在一个增强病变。MNE-GBM 患者的中位随访时间为 16.1 个月。最后一次随访时,所有患者均复发(中位 PFS 7.6 个月),11 名患者死亡。中位 OS 为 16.2 个月(95%CI,4.1-27.5)。11 名患者接受替莫唑胺同步放化疗作为初始治疗。8 名患者的放射野包括所有病变灶(增强和非增强病变),其中 5 名在非增强病变内进展。3 名患者未对整个非增强病变进行放疗,其中 2 名在未放疗区域进展。总之,MNE-GBM 并不罕见,在单独的非增强病变中具有侵袭性进展的高风险。

相似文献

1
Multicentric non-enhancing lesions in glioblastoma: A retrospective study.多中心非强化病变在胶质母细胞瘤中的回顾性研究。
J Clin Neurosci. 2021 Mar;85:20-26. doi: 10.1016/j.jocn.2020.11.050. Epub 2021 Jan 3.
2
Prognosis prediction of measurable enhancing lesion after completion of standard concomitant chemoradiotherapy and adjuvant temozolomide in glioblastoma patients: application of dynamic susceptibility contrast perfusion and diffusion-weighted imaging.胶质母细胞瘤患者在完成标准同步放化疗及辅助替莫唑胺治疗后可测量强化病灶的预后预测:动态磁敏感对比灌注成像和扩散加权成像的应用
PLoS One. 2014 Nov 24;9(11):e113587. doi: 10.1371/journal.pone.0113587. eCollection 2014.
3
Efficacy of moderately hypofractionated simultaneous integrated boost intensity-modulated radiotherapy combined with temozolomide for the postoperative treatment of glioblastoma multiforme: a single-institution experience.适形调强同步推量放疗联合同步替莫唑胺化疗治疗多形性胶质母细胞瘤术后的疗效:单中心经验
Radiat Oncol. 2019 Jun 13;14(1):104. doi: 10.1186/s13014-019-1305-1.
4
Whole brain radiotherapy with concurrent temozolomide in multifocal and/or multicentric newly diagnosed glioblastoma.多灶性和/或多中心初诊胶质母细胞瘤行全脑放疗同步替莫唑胺化疗。
J Clin Neurosci. 2019 Oct;68:39-44. doi: 10.1016/j.jocn.2019.07.065. Epub 2019 Aug 6.
5
Baseline single institutional retrospective review of body mass index (BMI) as a prognostic indicator in patients with newly diagnosed glioblastoma (GBM).对新诊断的胶质母细胞瘤(GBM)患者的体重指数(BMI)作为预后指标的单机构回顾性基线研究。
J Clin Neurosci. 2024 Sep;127:110754. doi: 10.1016/j.jocn.2024.07.015. Epub 2024 Jul 27.
6
Hypofractionated accelerated radiotherapy (HART) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: a phase II randomized trial (HART-GBM trial).新诊断的胶质母细胞瘤中同步和辅助替莫唑胺的低分割加速放疗(HART):一项 II 期随机试验(HART-GBM 试验)。
J Neurooncol. 2018 Oct;140(1):75-82. doi: 10.1007/s11060-018-2932-3. Epub 2018 Jun 23.
7
Retrospective comparison of standard and escalated doses of radiotherapy in newly diagnosed glioblastoma patients treated with concurrent and adjuvant temozolomide.在接受同步和辅助替莫唑胺治疗的新诊断胶质母细胞瘤患者中,标准剂量与递增剂量放疗的回顾性比较。
Indian J Cancer. 2019 Jan-Mar;56(1):59-64. doi: 10.4103/ijc.IJC_128_18.
8
The efficacy of hypofractionated radiotherapy (HFRT) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: A meta-analysis.同步和辅助替莫唑胺的低分割放疗在新诊断的胶质母细胞瘤中的疗效:一项荟萃分析。
Cancer Radiother. 2021 Apr;25(2):182-190. doi: 10.1016/j.canrad.2020.08.049. Epub 2021 Jan 9.
9
Accelerated hyperfractionated radiochemotherapy with temozolomide is equivalent to normofractionated radiochemotherapy in a retrospective analysis of patients with glioblastoma.回顾性分析胶质母细胞瘤患者,替莫唑胺加速超分割放化疗与常规分割放化疗等效。
Radiat Oncol. 2019 Dec 12;14(1):227. doi: 10.1186/s13014-019-1427-5.
10
Hypofractionated versus standard radiation therapy in combination with temozolomide for glioblastoma in the elderly: a meta-analysis.老年胶质母细胞瘤中低分割放疗联合替莫唑胺与标准分割放疗的比较:一项荟萃分析。
J Neurooncol. 2019 Jun;143(2):177-185. doi: 10.1007/s11060-019-03155-6. Epub 2019 Mar 27.

引用本文的文献

1
Gyriform infiltration as imaging biomarker for molecular glioblastomas.脑回样浸润作为分子胶质母细胞瘤的影像生物标志物。
J Neurooncol. 2022 May;157(3):511-521. doi: 10.1007/s11060-022-03995-9. Epub 2022 Apr 1.